Hofseth BioCare Appoints Leif Arne Giske as New CFO

Norwegian biotech company Hofseth BioCare ASA has announced a significant management change, appointing Leif Arne Giske as the new Chief Financial Officer (CFO) effective immediately. Giske, who has been with Hofseth BioCare since 2013 and previously held the role of Group Accounting Manager, will now lead the financial management of the company.

In his new position, Giske will continue to play a key role in the company’s executive management team. He is already familiar with Hofseth BioCare’s unique business model, which upcycles side streams from the salmon industry to produce ingredients for both human and pet health. These include ProGo®, OmeGo®, and CalGo®/NT-II®.

Leif Arne Giske is now poised to bring his extensive experience in financial management to the forefront, ensuring the company’s financial operations run smoothly and efficiently. His transition into the CFO role underscores the company’s commitment to strengthening its internal structures and enhancing its financial oversight.

Hofseth BioCare, founded on the principles of sustainability and optimal utilization of natural resources, has grown significantly since its inception. The company’s innovative approach to ingredient production from salmon byproducts has made it a leader in the consumer and pet health sector. Through rigorous scientific research, Hofseth BioCare has established partnerships with leading academic institutions, identifying unique health benefits from its products.

Hofseth BioCare’s products, such as ProGo® and OmeGo®, are gaining recognition for their health benefits. ProGo® contains bioactive peptides and collagen, while OmeGo® is a whole salmon oil rich in fatty acids. CalGo®/NT-II® is a salmon bone powder used for bone and joint health. These products reflect the company’s dedication to using sustainable and traceable resources.

Jon Olav Ødegård, CEO of Hofseth BioCare ASA, emphasized the importance of this new leadership. “We are excited to welcome Leif Arne Giske to our executive team. His extensive experience in financial management will be invaluable as we continue to grow and innovate. We are confident that under his leadership, Hofseth BioCare will maintain its position as a leader in the industry.”

Giske holds 3,339,384 shares in Hofseth BioCare ASA, further aligning his interests with those of the company. With this appointment, Hofseth BioCare ASA is well-positioned to navigate the complexities of the global health and wellness market, driven by its commitment to sustainable practices and scientific research.

Hofseth BioCare ASA is listed on the Oslo Stock Exchange under the ticker "HBC," and the company continues to meet its disclosure requirements as mandated by Norwegian law.